4-(6-Fluorobenzisoxazol-3-yl)piperidine, a risperidone metabolite with serotonergic activity of potential clinical significance

Medicinal Chemistry Research

Volumn 6, Issue 9, 1996, Pages 593-601

  Iwamura, Tatsunori ^a   Casey, Christina T ^b   Young, Richard ^a   Dukat, Małgorzata ^a   Teitler, Milt ^b   Fadden, James S P ^c   Glennon, Richard A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0342993255     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. 2 antagonist properties. J. Pharmacol. Exp. Ther. 1988, 244, 685-693.
2. Leysen, J. E.; Gommeren, W.; Eens, A.; de Chaffoy de Courcelles, D.; Stoof, J. C.; Janssen, P. A. J. Biochemical profile of risperidone, a new antipsychotic. J. Pharmacol. Exp. Ther. 1988, 247, 661-670.
3. Gelders, Y. G.; Heylen, S. L. E.; Vanden Bussche, G.; Reyntjens, A. J. M.; Janssen, P. A. J. Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 1990, 23, 206-211.
4. Strupczewski, J. T.; Allen, R. C.; Gardner, B. A.; Schmid, B. L.; Strache, U.; Giamkowski, E. J.; Jones, M. C.; Ellis, D. B.; Huger, F. P.; Dunn, R. W. Synthesis and neuroleptic activity of 3-(1-substituted-4-piperidinyl)-1,2-benzisoxazoles. J. Med. Chem. 1985, 28, 761-769.
5. Herndon, J. L.; Ismaiel, A.; Ingher, S. P.; Teitler, M.; Glennon, R. A. Ketanserin analogues: Structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J. Med. Chem. 1992, 35, 4903-4910.
6. Taylor, E. W.; Nikam, S.; Week, B.; Martin, A.; Nelson, D. Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A, and 5-HT2 recognition sites. Life Sci. 1987, 41, 1961-1969.
7. Meuldermans, W.; Hendrikx, J.; Mannens, G.; Lavrijsen, K.; Janssen, C.; Bracke, J.; Le Jeune, L.; Lauwers, W.; Heykants, The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab. Dispos. 1994, 22, 129-138.
8. Mannens, G.; Huang, M.-L.; Meuldermans, W.; Hendrickx, J.; Woestenborghs, R.; Heykants, J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab. Dispos. 1993, 21, 1134-1141.
9. 2 for 3 h to give the desired oxime. Also, because the final product, 6-FBIP hydrochloride (mp 293-295 °C) [4], did not analyze correctly for C in the original study, our product (mp 300-305 °C, decomp) was submitted to Atlantic Microlab for elemental analysis, C, H, and N were found to be within 0.4% of theory.
10. Leonhardt, S.; Gorospe, E.; Hoffman, B. J.; Teitler, M. Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine-1C and 5-hydroxytryptamine-2 receptors. Mol. Pharmacol. 1992, 42, 328-335.
11. Glennon, R. A.; Dukat, M. Serotonin receptor subtypes. In: Psychopharmacology: The Fourth Generation of Progress. F. E. Bloom and D. J. Kupfer, eds., Raven Press, New York, 1995. pp 415-429.
12. Zifa, E.; Fillion, G. 5-Hydroxytryptamine receptors. Pharmacol. Rev. 1992, 44, 401-458.
13. 3H]8-OH DPAT as radioligand.
14. 1 value for curves obtained in the presence of 5-HT were not statistically different. Media was then aspirated and 1 mL of a methanol-water-HCl (25:25:1) mixture was added. Chloroform (0.5 vol) was added to create two phases and the upper phase was loaded on to a column (BioRad AG1-X8 resin). Total inositol phosphates were then collected according to the method of Berridge et al [27]. Scintillation cocktail (20 mL, Ecoscint, National Diagnostics) was added and the samples were counted and analyzed using GraphPad PRISM.
15. Glennon, R. A. Classical hallucinogens: An introductory overview In: Hallucinogens: An Update. G. Lin and R. A. Glennon, eds., U.S. Government Printing Office, Washington, D.C., 1994. pp 4-32.
16. Ismaiel, A. M.; De Los Angeles, J., Teitler, M.; Ingher, S.; Glennon, R. A. Antagonism of the 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2 versus 5-HT1C selective antagonist. J. Med. Chem. 1993, 36, 2519-2525.
17. Schreiber, R.; Brocco, M.; Millan, M. J. Blockade of the discriminative stimulus effects of DOI by MDL 100,907, and the atypical antipsychotics clozapine and risperidone. Eur. J. Pharmacol. 1994, 264, 99-102.
18. Glennon, R. A.; Young, R.; Rosecrans, J. A. Antagonism of the effects of the hallucinogen DOM and the purported serotonin agonist quipazine by 5-HT2 antagonists. Eur. J. Pharmacol. 1983, 91, 189-194.
19. McEvoy, J. P.; Efficacy of risperidone on positive features of schizophrenia. J. Clin. Psychiat. 1994, 55 (Suppl 5), 18-21.
20. Marder, S. R., Meibach, R. C. Risperidone in the treatment of schizophrenia. Am. J. Psychiat. 1994, 151, 825-835.
21. Leysen, J. E.; Janssen, P. F.; Megans, A. A. H. P., Schotte, A. Risperidone. A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacological activity. J. Clin. Psychiat. 1994, 55 (Suppl 5), 5-12.
22. Schotte, A.; Janssen, P. F. M.; Gommeren, W.; Luyten, W. H. M. L.; Van Gompel, P.; Lesage, A. S.; De Loore, K.; Leysen, J. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding Psychopharmacology 1996, 124, 57-73.
23. Hertel, P.; Nomikos, G. G.; Iurlo, M.; Svensson, T. H. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology 1996, 124, 74-86.
24. Potter, W. Z.; Manji, H. K. Antidepressants, metabolites and apparant drug resistance. Clin. Neuropharmacol. 1990, 13 (Suppl 1), S45-S53.
25. Caccia, S. In vivo metabolism of 4-substituted arylpiperazines to pharmacologically active 1-aryl-piperazines. Bull. Chim. Farm. 1990, 129, 183-188.
26. 2 antagonists with potential atypical antipsychotic activity: Antipsychotic profile of Iloperidone (HP 873). J. Med. Chem. 1995, 38, 1119-1131.
27. Berridge, M. J.; Downes, C. P.; Hanley, M. R. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem. J. 1982, 206, 587-595.